Usa hospital Food Depression patient Target Strategy ADHD Research and News Usa

Spravato Approved for Treatment-Resistant Depression

Reading now: 973
additudemag.com

February 25, 2025Spravato, the esketamine nasal spray approved in 2019 for use alongside oral antidepressants for treatment-resistant depression, has been approved by the U.S.

Food and Drug Administration (FDA) as a standalone monotherapy with no oral medication required.Esketamine is a form of the dissociative agent ketamine, commonly used as an anesthetic; it works by targeting the neurotransmitter glutamate.

According to a randomized, double-blind, placebo-controlled study, 22.5% of patients who took Spravato alone for four months achieved remission from depression (as measured by MADRS) compared with 7.6% of patients taking placebo.1Common side effects in clinical trials were disassociation, dizziness, nausea or vomiting, sedation, headache, decreased sensitivity, anxiety, increased blood pressure, and feeling of intoxication.

Due to these potential risks, the treatment is available only through the Risk Evaluation and Mitigation Strategy Program and must be self-administered in certified health care settings.

Read more on additudemag.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA